The flashcards below were created by user
MeganM
on FreezingBlue Flashcards.
-
a prodrug metabolized to its active form by CYP 2C19
Clopidigril (plavix)
-
Do not administer ________ with drugs that inhibit 2C19.
Clopidigrel (plavix)
-
Drugs that work in distal tubule to ↑ Na excretion 5-10%
- Thiazides
- Metolazone
- K+ sparing aldosterone antagonists
-
How do diuretics work?
decrease renal Na+ reabsorption, which reduces water reapsorption
-
_________ diuretics are used to alleviate congestive symptoms.
Loop
-
________ diuretics inhibit reabsorption of Ca++ and Mg+ back into systemic circulation.
Loop
-
________ diuretics can mimic a sulfa allergy.
loop
-
Electrolyte-related AE of loop diuretics.
- Hypocalcemia
- Hypomagnesemia
- Hypokalemia (increase K+ excretion)
-
_______ diuretics can have dose-related ototoxicity.
loop
-
Loop or thiazide diuretics better for HF? for HTN?
-
_________ are ineffecive as monotherapy if GFR less than 30.
thiazides
-
________ sometimes coadministered with loop diuretics if reduced GFR.
Metolazone
-
Avoid _______ in patients with elevated Scr (>2-2.5)
loop diuretics
-
Competitive antagonism of Na+-Cl- cotransporter .
Thiazide diuretics
-
Thiazide diuretics result in decrease in _______ and have a direct _______ effect.
- intravascular volume
- vasodilatory
-
AE of thiazides.
- hypokalemia
- hyperuricemia
- hyperglycemia
- dehydration
-
Cause Na+ channel blockade; increase reabsorption of potassium into plasma from renal tubules.
Potassium-sparing Diuretics
-
AE of Potassium-sparing Diuretics.
hyperkalemia
-
Potassium-sparing diuretics are mostly used in combo with __________. Why?
- HCTZ/TMT (Maxide)
- If used alone, can cause hyperkalemia
-
Decreases K+/Na+ exchange in distal tubule and collecting duct of nephron
Aldosterone Antagonist
-
Diuretic that inhibits both androgen and mineralocorticoid receptors
Spironolactone (Aldactone)
-
Diuretic that is more selective for mineralocorticoid receptors = Less AE.
Eplerenone (Inspra)
-
When would you NOT use a BB?
acute decompensated HF
-
Attenuation of cytotoxic and signaling effects of circulating catecholamines, which induce sympathetic tone, increase HR, and can increase pathogenesis of HF.
β-Blockers
-
________ can be beneficial for and may help prevent acute coronary syndrome.
β-Blockers
-
Pts without s/s may not realize benefit of ACEI and BB b/c they are not necessarily used for symptomatic relief, they are used for mortality & survival benefits.
ACEI & BB
-
_______ agonize β receptors to increase contractility
catecholamines
-
β-Blockers cause antagonism of _________.
catecholamines
-
How do β-Blockers decrease C.O.?
by decreasing heart rate and contractility, which decreases BP (catecholamine antagonism)
-
What happens with PVR initially with BB?
body compensates for decrease in BP by increasing PVR
-
What happens in the long run with BB and PVR?
they decrease PVR by inhibiting β-receptors in kidney, which decreases renin (decreases BP by decreasing vasoconstriction & Na+ & water retention)
-
_________ produce resting bradycardia and therefore reduce exercise-induced tachycardia.
BB
-
Can cause AV block; risk is increased when used with Digoxin.
BB
-
Can mask s/s of hypoglycemia.
BB
-
Detrimentally affects lipid profile (can cause hyperlipidemia!).
BB
-
B-2 receptors cause bronchoconstriction, so pts with asthma should NOT be on a __________.
non-selective BB
-
Why should a pt avoid sudden w/d of BB?
body compensates by upregulating beta receptors, so when you abruptly stop, you have more beta receptors available for catecholamine action → rebound HTN, tachycardia
-
Antagonizes catecholamines at β1 and β2 receptors, inhibition of sympathetically induced renin secretion
Non-selective β-Blockers
-
Why are non-selective β-Blockers contraindicated in pts with asthma?
they block B-2 receptors and cause bronchoconstriction
-
Two types of selective β-Blockers.
-
Metoprolol is hepatically metabolized by _________.
CYP2D6
-
Selective β-Blocker that has dose-dependent cardioselectivity.
Metoprolol
-
Selective β-Blocker that is less lipid-soluble and more water-soluble.
Atenolol
-
Why does it matter that atenolol is more water-soluble than metoprolol?
it is less metabolized, and will be even more slowly metabolized in pts with renal dysfunction
-
Acebutolol, carteolol, penbutolol, pindolol
Partial β-Blockers (mixed agonist-antagonist)
-
Benefit to Partial β-Blockers over β-Blockers.
Less resting bradycardia (act as agonist when sympathetic tone is low)
-
Labetalol and Carvedilol
Mixed α1/β1/2 Blockers
-
Precaution: “first dose effect” – postural hypotension, body will eventually compensate, but can titrate slowly over time or give at bedtime
α1- Blockers
-
What do you need to give with α1- Blockers? Why?
- diuretic
- w/o it, there will be Na+ & H2O retention
-
Inhibit peripheral vasomotor tone, reducing vasoconstriction and decreasing SVR, which decreases BP
α1- Blockers
-
What are α1- Blockers used to treat?
BPH
-
How are α1- Blockers metabolized?
hepatic ally, non-CYP
-
Reduce sympathetic outflow from vasopressor centers in the brain stem, so work in CNS
Centrally Acting Agents (alpha-2 agonists)
-
Reverses vasoconstriction and volume retention that is caused by renin-angiotensin-aldosterone system activation
ACE Inhibitors
-
What happens with abrupt w/d of Clonidine?
Rebound hypertension (downregulates alpha-2 receptors, once drug is removed, there is less feedback inhibition)
-
What happens when TCA's are administered with Clonidine?
effect of Clonidine is blocked (b/c TCA’s inhibit reuptake of NE & will increase action of catecholamines further)
-
How is Clonidine metabolized?
50/50 hepatic metabolism and renal excretion
-
Block ACE conversion of angiotensin I to angiotensin II; *also block inactivation of bradykinin
ACE Inhibitors
-
__________ are beneficial for diabetics with proteinuria.
ACEI
-
Elicits maximal response; Stabilizes DR*
Full agonist
-
Stabilizes DR and DR*
Partial or mixed agonist-antagonist
-
Stabilizes DR in the case of R*
Inverse - inactivates free active receptors
-
Stabilization of DR; Prevention of DR*
ANTAGONISTS
-
reversible binding, active site
Competitive antagonist
-
irreversible active site or allosteric site
Noncompetitive antagonist
-
MOA: Na channel blockade in collecting duct, increased K reabsorption
- K sparing:
- Triamterene, amiloride
-
MOA: inhibit Na-K-CL cotransporter in loop of Henle
- Loop diuretics:
- Furosemide, bumetanide, torsemide
-
MOA: competitive antagonism of Na-Cl transporter in distal tubule
Thiazides
-
MOA: competitive antagonist at aldosterone receptor; inhibits mineralcorticoid receptors
- Aldosterone antagonist:
- Spironolactone, eplerenone
-
Less effective if CrCl <30 (diuretic)
Thiazides
-
Diuretic that alleviates congestive sxs of HF
Loop
-
AE: dose related ototoxicity, ↓ Mg, ↓ Ca, “sulfa” allergy
Loop
-
What drug would be a good choice for someone with HTN and BPH?
Prazosin α1 blocker
-
AEs if Dihydropyridines.
- peripheral edema,
- dizziness,
- headache,
- flushing,
- reflex tachycardia,
- constipation
-
|
|